OPK

OPKO Health, Inc. - 2007 Annual Report (10-K) Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2007. OPKO Health, Inc. (formerly eXegenics, Inc.) is a specialty healthcare company focused on ophthalmic pharmaceuticals and diagnostic instrumentation. The reporting period reflects significant corporate restructuring, including a reverse merger with Froptix Corporation and the acquisition of Acuity Pharmaceuticals, Inc. in March 2007, and the acquisition of Ophthalmic Technologies, Inc. (OTI) in November 2007. These transactions transitioned the company from a development-stage entity to one with commercial revenue streams in ophthalmic instrumentation.

Key Financial Metrics

Note: The 2007 Net Loss includes a non-cash write-off of $243.8 million for acquired in-process research and development (IPR&D) related to the Acuity acquisition.

Material Changes vs. Prior Period

• Revenue Generation: The company generated its first revenue ($0.8 million) in 2007 following the acquisition of OTI in November. Prior to this, the company had no revenue.
• Expense Surge: Operating expenses increased from $0.9 million in 2006 to $267.2 million in 2007. This was primarily driven by the $243.8 million immediate expensing of Acuity's IPR&D assets and increased R&D costs ($10.9 million) for the Phase III clinical trial of bevasiranib.
• Liquidity Position: Cash and cash equivalents grew from $0.1 million to $23.4 million, funded by a $20 million private placement to The Frost Group and borrowings under a related-party credit line.
• Debt Assumption: The company assumed a $4.0 million term loan and a $12.0 million line of credit from Acuity, resulting in total debt of approximately $14.6 million at year-end.

Guidance, Outlook, and Risks

Outlook and Management Commentary: Management expects to continue incurring substantial losses as it advances the development of its lead product candidate, bevasiranib (for Wet AMD), and expands its instrumentation business. The company initiated the pivotal Phase III COBALT trial for bevasiranib in July 2007. Management believes cash on hand is sufficient to fund operations for at least the next 12 months but anticipates a need for additional capital to complete clinical trials and commercialization efforts.

Material Risks and Contingencies:

• FDA Warning Letter: In March 2008 (subsequent to year-end), the FDA issued a warning letter to OTI regarding quality system deficiencies. This resulted in an Import Alert, preventing the sale of certain OTI devices (Scan 1000, Scan 2000, OCT/SLO) in the United States until violations are corrected.
• Regulatory Approval: The company has no approved pharmaceutical products. Success is highly dependent on the regulatory approval of bevasiranib, which is currently in Phase III trials.
• Profitability: The company has a history of operating losses and does not expect to become profitable in the near future.
• Capital Requirements: Substantial additional funding is required for clinical trials and commercialization, which may not be available on acceptable terms.

Investor Verification Checklist

• FDA Compliance Status: Verify the current status of the FDA warning letter issued to OTI in March 2008 and the timeline for resolving the Import Alert affecting U.S. sales.
• Bevasiranib Clinical Progress: Monitor the enrollment and interim results of the Phase III COBALT trial and the planned initiation of the CARBON trial.
• Cash Burn Rate: Assess the sufficiency of the $23.4 million cash balance against the projected $25 million cost for the ongoing Phase III trial and general operating expenses.
• Debt Obligations: Review the terms of the $12 million related-party credit line (due July 2009) and the repayment status of the Horizon term loan (repaid in full in Jan 2008).
• Related Party Transactions: Note the significant concentration of ownership and financing from The Frost Group, including the $20 million equity investment and the credit facility.